Navigation Links
NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders
Date:12/5/2013

LOS ANGELES, Dec. 5, 2013 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/898,675 entitled "Systems, Devices and Methods For Treatment of Neurological Disorders and Conditions." The patent application, exclusively licensed to NeuroSigma, is owned by The Regents of the University of California (Regents) as a result of research conducted by physicians and scientists at the University of California, Los Angeles (UCLA). Morgan, Lewis & Bockius LLP has represented the Regents in the prosecution of this patent application and other related applications. Haynes & Boone LLP has represented NeuroSigma.

The method and system claims of the patent application cover the use of trigeminal nerve stimulation (TNS) with cutaneous electrodes for the treatment of neurological disorders, including but not limited to epilepsy, movement disorders, migraine, daily chronic headache, and acute brain injury. 

"We applaud Dr. Christopher DeGiorgio, Dr. Ian Cook and the other inventors for developing this non-invasive neuromodulation technology," said Leon Ekchian, Ph.D., President & CEO of NeuroSigma. "NeuroSigma has the exclusive rights to a large portfolio of pending TNS-related US patent applications and their foreign counterparts. We are delighted to have received our second Notice of Allowance related to this portfolio. Together with the issued patent covering neuropsychiatric applications of eTNS, this will further strengthen our position in the marketplace," added Dr. Ekchian.

The development of TNS for neurological indications has been spearheaded by Christopher DeGiorgio, M.D., Vice President of Neurology at NeuroSigma, and Professor of Neurology at UCLA. "As an inventor, I am
'/>"/>

SOURCE NeuroSigma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeuroSigma Announces FDA Approval to Commence Phase III Trial
2. NeuroSigma Announces Debut of Its Monarch eTNS System in Canada
3. NeuroSigma Launches Dedicated Website to Introduce Its Monarch eTNS System for Epilepsy and Depression
4. NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive Disorder
5. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
6. NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy
7. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
8. NeuroSigma Receives CE Certification
9. NeuroSigma Receives Global Quality Control Certification
10. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
11. Soligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015  CytomX Therapeutics, Inc., a biopharmaceutical company developing ... the filing of a registration statement on Form S-1 ... to a proposed initial public offering of its common ... the price range for the offering have not yet ... under the symbol "CTMX" on the NASDAQ Global Market. ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Originally discovered ... as Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory ... by Senju Pharmaceutical Co., Ltd under the trade ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... Capacity and Production" report to their offering. ... Survey of Biopharmaceutical Manufacturing Capacity and Production is ... contract manufacturing organizations, current and projected future capacity ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... N.C., June 20, 2011 Pharmaceutical Institute, the ... pharmaceutical and biotech industry and a subsidiary of ... updates to its Therapeutic Area Essentials™ ... disease state training for pharmaceutical and biotech R&D ...
... dreamed of becoming a pilot for as long as he can ... child opting to play with toy planes instead of cars, and ... a family trip to Disney World.  At 8-years old Baniecki scribbled ... airline pilot and placed it into a time capsule.  Ten years ...
Cached Medicine Technology:Therapeutic Area Essentials "Class of 2011" Brings Current Disease State Training to Pharma 2Pilot's Dream Comes True Thanks to New Robotic Surgery 2Pilot's Dream Comes True Thanks to New Robotic Surgery 3Pilot's Dream Comes True Thanks to New Robotic Surgery 4
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle ... 15 seconds of unique footage that users can shrink and stretch in the Final ... more. Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... the company to freely market and sell Arterosil and Arterosil HP, and that ... Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United States ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... No Malaria Day at the Zoo to celebrate children helping children, a thank ... their congregations throughout West Ohio have contributed to the United Methodist initiative to ...
(Date:8/28/2015)... ... , ... For Dallas, the time is nearing for the annual Heart Walk, ... , The American Heart Association hosts their well-known Heart Walk to raise money in ... difference can be made. Walkers can participate in the cause and someone can also ...
(Date:8/28/2015)... ... , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance abuse ... Mission” benefit concert in Mendon, IL. Held in the Show Barn at the Adams ... education programs in the underfunded local school districts of Mendon at neighboring Quincy, IL. ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... with profound hearing disabilities and President A.P.J.Abdul Kalam today ... to intensify their drive to reduce the number of ... the 3rd Cochlear Implant Group of India Conference in ... with severe hearing disability, 0.9 million people with moderate ...
... has been found to have less side effects and ... the allergen is given as a vaccine in order ... antibodies which are already present helps to counteract the ... injections against allergy diseases such as hay fever, cat ...
... leader Colgate-Palmolive Company has entered into an alliance with ... designed to fight against pre-cancerous //conditions in the oral ... this end Colgate purchased $20 million of Introgen shares ... by Introgen. Introgen has a wide range of molecular ...
... November issue of the Journal of the National Cancer Institute, ... treatment, and patients treated with the higher chemotherapy dose had ... testicular cancer is the most common cancer among 20-40 year ... age at which they are starting a family, and the ...
... that rheumatoid arthritis patients respond differently to the same ... new study now explains that it is due to ... following experiments conducted on animal models of mouse that ... such complex behaviors could enable physicians make an individualized ...
... FDA approved long-term treatment regime for patients with treatment ... now being offered to patients at NewYork-Presbyterian Hospital/Columbia University ... first treatment specifically approved for TRD in patients over ... been unsuccessful atleast in four or more of the ...
Cached Medicine News:Health News:Kalam Appeals to Eradicate Hearing Disability 2Health News:Oral Edible vaccine for Allergy Vaccines 2Health News:Decline in Paternity Rates Following Treatment for Testicular Cancer 2Health News:Study Offers Insights Into Treatment Of Rheumatoid Arthritis 2Health News:FDA Approved Nerve-Stimulation Therapy Now Available In New York 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: